Company Information


London, UK


Christian Itin


Autolus was founded on advanced cell programing technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014.

Autolus is committed to bringing life-changing treatments to cancer patients by using its broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill these cells. Autolus believe its programmed T cell therapies have the potential to offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours.

Latest Updates

Arix Bioscience plc Autolus announces closing of public offering

16th April 2019

Autolus announces pricing of public offering

11th April 2019

Autolus announces launch of proposed public offering in the US

9th April 2019

Autolus presents initial AUTO1 data at AACR

1st April 2019

Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019

29th March 2019

Autolus hosts R&D day and provides update on AUTO3

26th March 2019

Autolus presents initial AUTO3 data at ASH

3rd December 2018

Autolus announces update on AUTO4 and AUTO5 programmes

3rd December 2018

Autolus Therapeutics to Present New Data at the ASH Annual Meeting

2nd November 2018

Autolus announces closing of IPO

26th July 2018

Update on Autolus proposed initial public offering in the United States

8th June 2018

Autolus files for proposed initial public offering in the United States

8th May 2018

Former Chief Operating Officer of Kite Pharma, Cynthia M. Butitta, appointed to Autolus’ Board of Directors

12th March 2018

Autolus announces confidential submission of draft registration statement for potential initial public offering in the United States

6th March 2018

Publication of Pre-clinical data of a dual targeting CAR for treatment of Multiple Myeloma

2nd January 2018

Autolus announces publication in Nature

14th November 2017

Arix Bioscience participates in $80 million Series C financing for Autolus

26th September 2017

Arix Bioscience plc notes positive clinical study announcements from Autolus Limited

18th September 2017


3rd March 2016